ArticleScientific reports2026
Sexual dysfunction in Brazilian women undergoing adjuvant endocrine therapy for breast cancer: prevalence and associated factors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to describe the frequency of sexual dysfunction among women undergoing adjuvant endocrine therapy (ET) and explore its relationship with patients' clinical, social, and demographic characteristics. We evaluated women with a history of non-metastatic estrogen receptor-positive invasive breast carcinoma who had been receiving adjuvant ET for at least 6 months and reported at least one instance of sexual intercourse 4 weeks prior to study entry. Sexual dysfunction was assessed using the Female Sexual Function Index (FSFI). Demographic and medical information were extracted from medical records and data were analyzed using R software. Between June 2021 and March 2024, a total of 774 patients were recruited. The mean age was 56.5 years. The mean duration of ET was 3.2 years. Only 346 patients (44.8%) had engaged in sexual intercourse in the previous 4 weeks and among them, 276 (79.8%) reported sexual dysfunction (mean FSFI score = 20.83, standard deviation SD = 6.3). Patient with sexual dysfunction were older than those without (53 ± 10.4 vs. 48 ± 9.4 p = 0.0002) and exhibited significantly lower EORTC QLQ C30 and BR23 scores. The use of aromatase inhibitors (AI) versus tamoxifen was associated with sexual dysfunction, with a prevalence ratio of 1.17 for sexual dysfunction (p = 0.047). In this study 79.8% of patients experienced sexual dysfunction. Interventions, such as sex training by cancer professionals, patient education, and integrated survivorship programs could enhance the quality of life of these patients. Sexual dysfunction is a prevalent and impactful issue among breast cancer survivors undergoing ET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.